Cytek Biosciences reports Q3 EPS (4c), consensus 1c

Reports Q3 revenue $52.29M, consensus $51.14M. “Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said Wenbin Jiang, CEO of Cytek Biosciences (CTKB). “As we look ahead, our team remains sharply focused on expanding our global installed base, growing our recurring revenue streams and on profitability and cash generation. While we remain mindful of market conditions, we believe Cytek is well-positioned to deliver long-term value for all of our stakeholders through the strong and disciplined execution of our strategic priorities.”